American Century Companies Inc. Has $1.36 Million Stock Holdings in Replimune Group, Inc. (NASDAQ:REPL)

American Century Companies Inc. grew its position in Replimune Group, Inc. (NASDAQ:REPL) by 32.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 111,850 shares of the company’s stock after buying an additional 27,259 shares during the period. American Century Companies Inc.’s holdings in Replimune Group were worth $1,355,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. boosted its stake in Replimune Group by 12.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company’s stock valued at $5,313,000 after acquiring an additional 52,498 shares during the last quarter. BNP Paribas Financial Markets boosted its position in shares of Replimune Group by 81.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company’s stock worth $165,000 after purchasing an additional 6,748 shares during the last quarter. State Street Corp grew its stake in shares of Replimune Group by 102.1% during the third quarter. State Street Corp now owns 2,340,042 shares of the company’s stock worth $25,647,000 after purchasing an additional 1,182,181 shares during the period. Barclays PLC increased its holdings in Replimune Group by 165.5% in the third quarter. Barclays PLC now owns 158,491 shares of the company’s stock valued at $1,738,000 after purchasing an additional 98,791 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Replimune Group by 17.9% in the third quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock valued at $15,657,000 after buying an additional 217,308 shares during the period. Institutional investors own 92.53% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. HC Wainwright increased their price target on shares of Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. increased their target price on shares of Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Finally, BMO Capital Markets boosted their price target on shares of Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $19.43.

Replimune Group Stock Up 2.4 %

NASDAQ:REPL opened at $7.31 on Thursday. Replimune Group, Inc. has a twelve month low of $4.92 and a twelve month high of $17.00. The firm has a market capitalization of $562.98 million, a price-to-earnings ratio of -2.38 and a beta of 1.26. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14. The stock’s 50 day moving average price is $11.61 and its two-hundred day moving average price is $11.94.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). Equities research analysts expect that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.